Evaluating polygenic risk scores in assessing risk of nine solid and hematologic cancers in European descendants

Jungyoon Choi, Guochong Jia, Wanqing Wen, Jirong Long, Wei Zheng, Jungyoon Choi, Guochong Jia, Wanqing Wen, Jirong Long, Wei Zheng

Abstract

Genome-wide association studies (GWAS) have identified many genetic risk variants for cancers. The utility of these variants in assessing risk of esophageal, gastric and endometrial cancers, as well as melanoma, glioma, diffuse large B-cell lymphoma, follicular lymphoma, chronic lymphoid leukemia and multiple myeloma, has not been adequately investigated. We constructed a site-specific polygenic risk score (PRS) for each of these nine cancers using their GWAS-identified risk variants. Using data from 400 807 participants of European descent in the UK Biobank, a population-based cohort study, we estimated the hazard ratios of each cancer associated with its PRS using Cox proportional hazard models. During a median follow-up of 5.8 years, 3905 incident cases of these nine cancers were identified in the cohort. The area under the receiver operating characteristic curve ranged from 0.53 to 0.69 for these cancers. Except for esophageal cancer, significant dose-response associations were observed between PRS and cancer risk. Compared to individuals in the middle quintile (40%-60%) at an average risk, those among the highest 5% of the PRS had a twofold elevated risk of melanoma, glioma, follicular lymphoma or multiple myeloma, and a fourfold elevated risk of chronic lymphoid leukemia. Using PRS, 63.0% of the participants could be classified as having an over twofold elevated risk for at least one cancer. The PRS derived using risk variants identified to date by GWAS showed the potential in identifying individuals at a significantly elevated risk of cancer for prevention.

Keywords: cancer; genetics; genome-wide association study; polygenic risk score.

© 2020 UICC.

References

REFERENCES

    1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394-424.
    1. Nagy R, Sweet K, Eng C. Highly penetrant hereditary cancer syndromes. Oncogene. 2004;23:6445-6470.
    1. Yurgelun MB, Kulke MH, Fuchs CS, et al. Cancer susceptibility gene mutations in individuals with colorectal cancer. J Clin Oncol. 2017;35:1086-1095.
    1. Oeffinger KC, Fontham ETH, Etzioni R, et al. Breast cancer screening for women at average risk: 2015 guideline update from the American Cancer Society. JAMA. 2015;314:1599-1614.
    1. Walsh T, Casadei S, Coats KH, et al. Spectrum of mutations in BRCA1, BRCA2, CHEK2, and TP53 in families at high risk of breast cancer. JAMA. 2006;295:1379-1388.
    1. Tung N, Domchek SM, Stadler Z, et al. Counselling framework for moderate-penetrance cancer-susceptibility mutations. Nat Rev Clin Oncol. 2016;13:581-588.
    1. Easton DF, Pharoah PDP, Antoniou AC, et al. Gene-panel sequencing and the prediction of breast-cancer risk. N Engl J Med. 2015;372:2243-2257.
    1. Ma X, Zhang B, Zheng W. Genetic variants associated with colorectal cancer risk: comprehensive research synopsis, meta-analysis, and epidemiological evidence. Gut. 2014;63:326-336.
    1. Sud A, Kinnersley B, Houlston RS. Genome-wide association studies of cancer: current insights and future perspectives. Nat Rev Cancer. 2017;17:692-704.
    1. Bush WS, Moore JH. Chapter 11: genome-wide association studies. PLoS Comput Biol. 2012;8:e1002822.
    1. Gibson G. Rare and common variants: twenty arguments. Nat Rev Genet. 2012;13:135-145.
    1. Golan D, Lander ES, Rosset S. Measuring missing heritability: inferring the contribution of common variants. Proc Natl Acad Sci USA. 2014;111:E5272-E5281.
    1. Khera AV, Chaffin M, Aragam KG, et al. Genome-wide polygenic scores for common diseases identify individuals with risk equivalent to monogenic mutations. Nat Genet. 2018;50:1219-1224.
    1. Shieh Y, Fejerman L, Lott PC, et al. A polygenic risk score for breast cancer in U.S. Latinas and Latin-American women. J Natl Cancer Inst. 2020;112:djz174.
    1. Archambault AN, Su Y-R, Jeon J, et al. Cumulative burden of colorectal cancer-associated genetic variants is more strongly associated with early-onset vs late-onset cancer. Gastroenterology. 2020;158:1274-1286. e12.
    1. Zheng W, Wen W, Gao Y-T, et al. Genetic and clinical predictors for breast cancer risk assessment and stratification among Chinese women. J Natl Cancer Inst. 2010;102:972-981.
    1. Pashayan N, Pharoah PD, Schleutker J, et al. Reducing overdiagnosis by polygenic risk-stratified screening: findings from the Finnish section of the ERSPC. Br J Cancer. 2015;113:1086-1093.
    1. Lambert SA, Abraham G, Inouye M. Towards clinical utility of polygenic risk scores. Hum Mol Genet. 2019;28:R133-R142.
    1. Lecarpentier J, Silvestri V, Kuchenbaecker KB, et al. Prediction of breast and prostate cancer risks in male BRCA1 and BRCA2 mutation carriers using polygenic risk scores. J Clin Oncol. 2017;35:2240-2250.
    1. van Hagen P, Hulshof MCCM, van Lanschot JJB, et al. Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med. 2012;366:2074-2084.
    1. Jia G, Lu Y, Wen W, et al. Evaluating the utility of polygenic risk scores in identifying high-risk individuals for eight common cancers. JNCI Cancer Spectrum. 2020;4:pkaa021.
    1. Sudlow C, Gallacher J, Allen N, et al. UKbiobank: an open access resource for identifying the causes of a wide range of complex diseases of middle and old age. PLoS Med. 2015;12:e1001779.
    1. 1000 Genomes Project Consortium, Auton A, Brooks LD, et al. A global reference for human genetic variation. Nature. 2015;526:68-74.
    1. Manichaikul A, Mychaleckyj JC, Rich SS, Daly K, Sale M, Chen W-M. Robust relationship inference in genome-wide association studies. Bioinformatics. 2010;26:2867-2873.
    1. Wang N, Lu Y, Khankari NK, et al. Evaluation of genetic variants in association with colorectal cancer risk and survival in Asians. Int J Cancer. 2017;141:1130-1139.
    1. Hemminki K, Li X, Czene K. Familial risk of cancer: data for clinical counseling and cancer genetics. Int J Cancer. 2004;108:109-114.
    1. Gu F, Chen T-H, Pfeiffer RM, et al. Combining common genetic variants and non-genetic risk factors to predict risk of cutaneous melanoma. Hum Mol Genet. 2018;27:4145-4156.
    1. Shi Z, Yu H, Wu Y, et al. Systematic evaluation of cancer-specific genetic risk score for 11 types of cancer in the cancer genome atlas and electronic medical records and genomics cohorts. Cancer Med. 2019;8:3196-3205.
    1. Kleinstern G, Camp NJ, Goldin LR, et al. Association of polygenic risk score with the risk of chronic lymphocytic leukemia and monoclonal B-cell lymphocytosis. Blood. 2018;131:2541-2551.
    1. Dai J, Shen W, Wen W, et al. Estimation of heritability for nine common cancers using data from genome-wide association studies in Chinese population. Int J Cancer. 2017;140:329-336.
    1. Lu Y, Ek WE, Whiteman D, et al. Most common ‘sporadic’ cancers have a significant germline genetic component. Hum Mol Genet. 2014;23:6112-6118.
    1. Morton LM, Slager SL, Cerhan JR, et al. Etiologic heterogeneity among non-Hodgkin lymphoma subtypes: the InterLymph Non-Hodgkin Lymphoma Subtypes Project. J Natl Cancer Inst Monogr. 2014;2014:130-144.
    1. Andrea M, De Roos Anneclaire J, Paolo B, et al. Occupation and risk of non-Hodgkin lymphoma and its subtypes: a pooled analysis from the InterLymph Consortium. Environ Health Perspect. 2016;124:396-405.
    1. Sellick GS, Goldin LR, Wild RW, et al. A high-density SNP genome-wide linkage search of 206 families identifies susceptibility loci for chronic lymphocytic leukemia. Blood. 2007;110:3326-3333.

Source: PubMed

赞助者和合作者

医疗条件

药物干预

3
订阅